Literature DB >> 1424408

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes.

U Breyer-Pfaff1, B Pfandl, K Nill, E Nusser, C Monney, M Jonzier-Perey, D Baettig, P Baumann.   

Abstract

In 26 hospitalized patients with depression, a combined pharmacogenetic test with dextromethorphan, a substrate of cytochrome P450IID6, and mephenytoin, the S-form of which is hydroxylated by a P450IIC isozyme, was carried out before amitriptyline therapy. Metabolites were determined in 24-hour urine samples collected on treatment day 8, and the contributions of individual compounds, including the four isomers of 10-hydroxyamitriptyline and 10-hydroxynortriptyline to total excretion were calculated. Formation of (-)-E-10-hydroxyamitriptyline and (-)-E-10-hydroxynortriptyline apparently depends on the activity of cytochrome P450IID6 because negative correlations existed between the log metabolic ratio of dextromethorphan and the relative quantities of these enantiomers. In contrast, correlations were positive for nortriptyline, (+)-E-10-hydroxynortriptyline, (-)-Z-10-hydroxynortriptyline, and (+)-Z-10-hydroxynortriptyline. The mephenytoin hydroxylase seems to participate in side-chain demethylation to the secondary and primary amines, because the log metabolic ratio of mephenytoin correlated negatively with the relative quantity of E-10-hydroxydidesmethylamitriptyline and positively with that of amitriptyline and its N-glucuronide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424408     DOI: 10.1038/clpt.1992.155

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 5.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 9.  Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors:  C Nordin; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

10.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.